CA2918190C — Combination therapy comprising a cdk4/6 inhibitor and an aromatase inhibitor or fulvestrant for the treatment of cancer
Assigned to Novartis AG · Expires 2023-01-17 · 3y expired
What this patent protects
Disclosed herein is a pharmaceutical combination comprising (1) a first agent which is Compound A1, described by Formula A or a pharmaceutically acceptable salt thereof, and (2) a second agent which is an aromatase inhibitor or a pharmaceutically acceptable salt thereof. The desc…
USPTO Abstract
Disclosed herein is a pharmaceutical combination comprising (1) a first agent which is Compound A1, described by Formula A or a pharmaceutically acceptable salt thereof, and (2) a second agent which is an aromatase inhibitor or a pharmaceutically acceptable salt thereof. The described combinations are useful in treatment of cancer, including estrogen receptor positive breast cancer. (see above formula)
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.